Allurion Technologies jumps on Canadian weight-loss partnership
** Shares of healthcare firm Allurion Technologies ALUR.N rise 21.7% to $3.47 in extended trading ** ALUR partners with Minogue Medical to distribute weight-loss program in Canada ** Minogue Medical, a Canadian medical device distributor, will deliver Allurion's weight loss solutions, including its non-surgical gastric balloon and digital care platform ** The partnership expands access to providers who can combine Allurion's program with GLP-1 weight loss therapy ** ALUR down 73% YTD (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Allurion Technologies
See all newsBrief: Allurion Technologies Inc - Sees Growing Demand From Patients Discontinuing Glp-1 Therapy
Brief: Allurion Intends To Appeal NYSE Notice Of Delisting, Execute Plan To Regain Compliance, And Expects To Continue Trading On NYSE
Brief: NYSE To Commence Delisting Proceedings Against Allurion Technologies, Inc.
Allurion rises on plan to offer discounted weight-loss drug Mounjaro in Argentina
Allurion rises after strong weight-loss data from combination therapy